A woman uses the touchscreen of her Amia device on her bedside table

Amia APD System With Sharesource Connectivity Platform


Help patients choose automated peritoneal dialysis (APD) with confidence

The Amia APD System powered by the Sharesource Connectivity Platform is designed to simplify home peritoneal dialysis for both clinicians and patients. It provides a user-friendly PD experience that guides patients through set up and treatment in the comfort of their own homes.1

Woman on laptop viewing Sharesource remote patient management

Features: Learn how the Amia APD System can work for patients

A women reads in bed with her Amia system on her nightstand
Voice guidance

Simple, voice-guided, step-by-step instructions guide patients through details  on how to set up and complete treatments.1 Built-in technical support features assist patients and, if necessary, provide contact information for help. The Amia system can speak to patients in English, Spanish or French Canadian.

The Amia system is the first and only peritoneal dialysis system in the U.S. equipped with voice guidance.1

Remote monitoring

The innovative Sharesource Connectivity Platform enables timely monitoring of patients’ historical treatment data. Sharesource Connectivity Platform establishes two-way connection between each patient’s Amia System and their clinic.2

Touchscreen interface

A large, intuitive touchscreen with graphics and animations guides patients through every step of their therapy, making it easy to learn and simple to perform.

Animation

Patients’ home PD therapy navigation is enhanced with simple, full-color animations. These are designed to help patients follow along with detailed steps, such as proper connect/disconnect procedures and aseptic technique.

Portability

The Amia system's compact size is designed for ease of use and storage at home. When patients are on the go, it can be packed in an optional convenient TSA-compliant carry-on case.1

 

Vantive offers a Global Travel Club to assist PD patients with travel. Visit PD Empowers to learn more.

SMART software

The SMART software on the Amia system includes advanced features that keep the patient's therapy within the programmed parameters.

  • SMART Therapy: The Amia system may provide a more effective treatment than standard tidal therapy because with SMART Therapy, patients receive the benefits of tidal fills and drains while still receiving all of the prescribed total night therapy volume.1
  • SMART Drain: If a drain alarm occurs during the night portion of therapy, the patient can activate a SMART Drain. This may allow a patient who experiences drain alarms while on therapy to complete the remainder of the night therapy.1
  • SMART Dwells: If the SMART Dwells option is enabled by a clinician during programming, the Amia system will automatically adjust night dwell times for each cycle for the therapy to finish within the total night therapy time.3

Resources for patients and their caregivers

We see a hand interacting with the Amia system
Support for the Amia APD System

The Amia System with Sharesource Connectivity Platform is backed by Vantive's industry-leading service and support.

Simple voice-guided instructions walk patients through each step of their treatment.1 The built-in Sharesource Connectivity Platform lets healthcare providers monitor historical treatment data remotely,2 which may reduce the number of visits patients need to make to the clinic.4

AmiaCare

Vantive’s AmiaCare service provides proactive or “predictive” maintenance to the Amia Automated PD System with the Sharesource Connectivity Platform. Under a predictive maintenance service model, routine service is performed prior to any failures or therapy interruptions to help improve the patient's experience.


Patient testimonials

Ramedio's Story


Patient testimonials

JoAnn's Story


PD Empowers

Our PD Empowers website is an essential online resource for renal healthcare professionals and patients living with chronic kidney disease (CKD). The site provides a wealth of educational tools and resources, including access to our PD Excellence Academy, a first-of-its-kind accredited learning program for clinicians.

Two healthcare professionals looking at computer

Connect with us

For more information about the Amia APD System, connect with us.


Important Safety Information

Intended Use

The Amia Automated PD System is intended for automatic control of dialysate solution exchanges in the treatment of adult renal failure patients undergoing peritoneal dialysis. All therapies using the Amia Automated PD System must be prescribed and performed under the responsibility of a physician who is familiar and well informed about peritoneal dialysis.1

The Sharesource portal is intended for use by healthcare professionals to remotely communicate new or modified treatment parameters with compatible dialysis instruments and transfer completed treatment data to a central database to aid in the review, analysis, and evaluation of patients’ historical treatment results. This system is not intended to be a substitute for good clinical management practices, nor does its operation create decisions or treatment pathways.2

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

Vantive, Amia, and Sharesource are trademarks of Vantive Health LLC or its affiliates.

References
  1. Vantive Health LLC. Amia Automated PD System Patient Guide.

  2. Vantive Health LLC. Sharesource Connectivity Platform User Guide for Use with the Amia APD System.

  3. Vantive Health LLC. Amia Automated PD System Clinician Guide.

  4. Makhija D, Alscher MD, Becker S, et al. Remote monitoring of automated peritoneal dialysis patients: assessing clinical and economic value. Telemed J E Health. 2018;24(4):315-323.* 

    *Authors D. Makhija, J. Danek, T. Kudelka and M. Gellens are employees of Vantive Healthcare Corporation. Authors S. Laplante and J. Sloand were employees of Vantive Healthcare Corporation at the time of the study. Author K. McLeod is a consultant at Xcenda, funded by Vantive Healthcare Corporation to conduct the study. For all other authors, no competing financial interests exist.